Ana Llorente Izquierdo

Title(s)Assistant Adjunct Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
ORCID ORCID Icon0000-0001-8135-9186 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California San Diego (UC San Diego), San Diego, USAAssistant ProfessorPresentMicrobiome and liver disease
    University of California San Diego (UC San Diego), San Diego, USA Assistant Project Scientist07/2019Microbiome and liver disease
    University of California San Diego (UC San Diego), San Diego, USAPostdoctoral Scholar-Employee01/2018Microbiome and liver disease
    Autonomous University of Madrid (UAM), Madrid, SpainPh.D.01/2013Biomedicine, Pre-doctoral fellow (FPI)
    Faculty of Medicine, Autonomous University of Madrid (UAM). , Madrid, SpainMSs 09/2008Molecular Biomedicine
    Complutense University of Madrid (UCM), Madrid, SpainB.S.02/2008Biochemistry
    Collapse Awards and Honors
    National Institutes of Health NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM 2022  - 20271R01AA029106-01A1 Goblet cells and intestinal immune response in alcohol-associated liver disease
    UC San Diego, USA2021  - 2022Hispanic Center of Excellence (HCOE) Faculty Scholar and HCOE Award
    San Diego Digestive Diseases Research Center (SDDRC) and the Hellman Family Foundation2020  - 2021Jon I. Isenberg Fellowship Award
    UC San Diego, USA2020Hispanic Center of Excellence (HCOE) Faculty Scholar and HCOE Award
    National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award2019  - 2020Pilot project grant by the Southern California Research Center for ALPD
    American Association for the Study of Liver Diseases (AASLD), USA2018  - 2021Pinnacle Research Award
    National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award 2018  - 2019Pilot project grant by the Southern California Research Center for ALPD
    National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award 2017  - 2018Pilot project grant by the Southern California Research Center for ALPD
    Cell Mol Gastroenterol Hepatol. 2017 Feb 3;3(2):129-1302017The Cellular and Molecular Gastroenterology and Hepatology CMGH Award for second most downloaded
    18th Annual Symposium, Keck School of Medicine of the University of Southern California (USC), LA2016Best poster Award
    Ministry of Economy and Competitiveness (MINECO), Spain2012Pre-doctoral Internship fellowship (Olefsky's lab)
    XXXIV Spanish Association of Biochemistry and Molecular Biology (SEBBM) Congress2011Roche Best poster Award
    Ministry of Economy and Competitiveness (MINECO), Spain2008  - 2013Pre-doctoral fellowship (FPI)

    Collapse Overview 
    Collapse Overview
    The major focus of Dr. Llorente’s lab is to decipher the molecular mechanisms involved in the progression of liver diseases to discover therapies and molecular targets to alleviate it. She is an Assistant Professor at UC San Diego. Her research is focused on uncovering the intricacies of the gut microbiome-host immune system interactions during alcohol-associated liver disease.

    Her work published in Nature Communications demonstrated that gastric acid suppression contributes to alcohol-associated liver disease in mice and humans. This is mediated by the overgrowth of intestinal Enterococcus and its translocation to the liver. During her appointment as Assistant Professor in August 2019, their efforts studying the role of Enterococcus in alcohol-related liver disease resulted in a co-first authorship in the prestigious journal Nature (2020 Impact Factor = 49.962). Briefly, they reported that alcoholic hepatitis in humans is associated with the presence of a pore forming toxin called cytolysin produced by Enterococcus faecalis. They reported that cytolytic Enterococcus faecalis is a novel predictor of mortality in alcoholic hepatitis patients. Notably, the authors demonstrated the use of specific bacteriophages as a novel therapeutic strategy to reduce ethanol-induced liver injury in mice. Among other efforts, Dr. Llorente has also recently published as a co-first author in Cellular and Molecular Gastroenterology and Hepatology (2020 Impact Factor = 9.225). They assessed the contribution of intestinal α1-2-fucosylation to obesity and steatohepatitis in mice.

    Currently, Dr. Llorente is exploring whether modulation of goblet cells as sentinels of the intestinal homeostasis are good candidates to prevent translocation of bacteria and to reduce alcohol-associated liver disease.

    Dr. Llorente has contributed to 25 accepted publications in the field of intestinal microbiome, mycobiome, and liver disease and published first-author manuscripts in high impact journals such as Nature (2020 Impact Factor = 49.962), Nature Communications (2020 Impact Factor = 14.919), Cellular and Molecular Gastroenterology and Hepatology (2020 Impact Factor = 9.225) and co-authored in journals such as Journal of Hepatology (2020 Impact Factor = 25.083), Cell Host and Microbe journal (2020 Impact Factor = 21.023), Hepatology (2020 Impact Factor = 17.425) and Journal of Clinical Investigation (2020 Impact Factor = 14.808) among others.

    Collapse Research 
    Collapse Research Activities and Funding
    Goblet cells and intestinal immune response in alcohol-associated liver disease
    San Diego Digestive Diseases Research Center (SDDRC) and the Hellman Family Foundation Jon I. Isenberg Fellowship AwardJan 1, 2021 - Dec 31, 2021
    Role: PI
    UC San Diego Hispanic Center of Excellence (HCOE) Faculty ScholOct 1, 2020 - Oct 1, 2022
    Role: PI
    Unraveling the role of enteric gp130 in the regulation of mucosal immunity
    NIH/NIAAA PI5P50AA011999Jan 1, 2020 - Dec 31, 2020
    Role: PI
    Intestinal stem-cell proliferation and differentiation in alcoholic liver disease
    American Association for the Study of Liver Disease (AASLD) Pinnacle Research AwardJul 1, 2018 - Jun 30, 2021
    Role: PI
    Intestinal stem-cell proliferation and differentiation in alcoholic liver disease
    NIH/NIAAA 5P50AA011999Jan 1, 2018 - Dec 31, 2019
    Role: PI

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun. 2021 12 09; 12(1):7172. Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Meshgin N, Papachristoforou E, Argemi J, Mendes BG, Wang Y, Su H, Sun W, Llorente C, Hendrikx T, Liu X, Hosseini M, Kisseleva T, Brenner DA, Bataller R, Ramachandran P, Karin M, Fu W, Schnabl B. PMID: 34887405; PMCID: PMC8660815.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    2. Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice. Cells. 2021 06 14; 10(6). Cabré N, Duan Y, Llorente C, Conrad M, Stern P, Yamashita D, Schnabl B. PMID: 34198609; PMCID: PMC8232222.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    3. Intestinal α1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice. Cell Mol Gastroenterol Hepatol. 2021; 12(1):293-320. Zhou R, Llorente C, Cao J, Zaramela LS, Zeng S, Gao B, Li SZ, Welch RD, Huang FQ, Qi LW, Pan C, Huang Y, Zhou P, Beussen I, Zhang Y, Bryam G, Fiehn O, Wang L, Liu EH, Yu RT, Downes M, Evans RM, Goglin K, Fouts DE, Brenner DA, Bode L, Fan X, Zengler K, Schnabl B. PMID: 33631374; PMCID: PMC8166943.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    4. A Perspective Of Intestinal Immune-Microbiome Interactions In Alcohol-Associated Liver Disease. Int J Biol Sci. 2021; 17(1):307-327. Bruellman R, Llorente C. PMID: 33390852; PMCID: PMC7757023.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    5. Deficiency of Intestinal α1-2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice. Alcohol Clin Exp Res. 2020 09; 44(9):1842-1851. Zhou R, Llorente C, Cao J, Gao B, Duan Y, Jiang L, Wang Y, Kumar V, Stärkel P, Bode L, Fan X, Schnabl B. PMID: 32628772; PMCID: PMC7808344.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    6. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019 11; 575(7783):505-511. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, van der Donk WA, Young R, Lawley TD, Stärkel P, Pride D, Fouts DE, Schnabl B. PMID: 31723265; PMCID: PMC6872939.
      View in: PubMed   Mentions: 169     Fields:    Translation:HumansAnimalsCells
    7. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol. 2020 03; 72(3):391-400. Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, Liu J, Mogavero S, Bosques-Padilla F, Abraldes JG, Vargas V, Tu XM, Yang L, Hou X, Hube B, Stärkel P, Schnabl B. PMID: 31606552; PMCID: PMC7031049.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    8. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest. 2019 07 11; 129(10):4091-4109. Calvente CJ, Tameda M, Johnson CD, Del Pilar H, Lin YC, Adronikou N, De Mollerat Du Jeu X, Llorente C, Boyer J, Feldstein AE. PMID: 31295147; PMCID: PMC6763256.
      View in: PubMed   Mentions: 50     Fields:    Translation:AnimalsCells
    9. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2018 06; 67(6):2150-2166. Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. PMID: 29159825; PMCID: PMC5962369.
      View in: PubMed   Mentions: 81     Fields:    Translation:Animals
    10. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology. 2018 05; 67(5):1737-1753. Khanova E, Wu R, Wang W, Yan R, Chen Y, French SW, Llorente C, Pan SQ, Yang Q, Li Y, Lazaro R, Ansong C, Smith RD, Bataller R, Morgan T, Schnabl B, Tsukamoto H. PMID: 29108122; PMCID: PMC5906140.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    11. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017 10 16; 8(1):837. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. PMID: 29038503; PMCID: PMC5643518.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimalsCells
    12. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017 Jun 30; 127(7):2829-2841. Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. PMID: 28530644; PMCID: PMC5490775.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansAnimalsCells
    13. Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. Alcohol Clin Exp Res. 2016 12; 40(12):2604-2613. Inamine T, Yang AM, Wang L, Lee KC, Llorente C, Schnabl B. PMID: 27739086; PMCID: PMC5133156.
      View in: PubMed   Mentions: 14     Fields:    Translation:Animals
    14. Fast-Track Clearance of Bacteria from the Liver. Cell Host Microbe. 2016 07 13; 20(1):1-2. Llorente C, Schnabl B. PMID: 27414492.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    15. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016 Feb 10; 19(2):227-39. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. PMID: 26867181; PMCID: PMC4786170.
      View in: PubMed   Mentions: 134     Fields:    Translation:HumansAnimalsCells
    16. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol. 2016 Mar 01; 310(5):G310-22. Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. PMID: 26702135; PMCID: PMC4773827.
      View in: PubMed   Mentions: 22     Fields:    Translation:Animals
    17. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015 May 01; 1(3):275-284. Llorente C, Schnabl B. PMID: 26090511; PMCID: PMC4467911.
      View in: PubMed   Mentions: 62     Fields:    
    18. Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Mol Metab. 2015 May; 4(5):378-91. Mayoral R, Osborn O, McNelis J, Johnson AM, Oh DY, Izquierdo CL, Chung H, Li P, Traves PG, Bandyopadhyay G, Pessentheiner AR, Ofrecio JM, Cook JR, Qiang L, Accili D, Olefsky JM. PMID: 25973386; PMCID: PMC4421024.
      View in: PubMed   Mentions: 57     Fields:    
    19. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods. 2015 Jun; 421:44-53. Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. PMID: 25595554; PMCID: PMC4451427.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    20. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma. Int J Biochem Cell Biol. 2013 Nov; 45(11):2501-11. Castro-Sánchez L, Agra N, Llorente Izquierdo C, Motiño O, Casado M, Boscá L, Martín-Sanz P. PMID: 23954207.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    21. Progression of liver oncogenesis in the double transgenic mice c-myc/TGF α is not enhanced by cyclooxygenase-2 expression. Prostaglandins Other Lipid Mediat. 2013 Oct; 106:106-15. Llorente-Izquierdo C, Mayoral R, Cucarella C, Grau C, Alvarez MS, Flores JM, García-Palencia P, Agra N, Castro-Sánchez L, Boscá L, Martín-Sanz P, Casado M. PMID: 23579063.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    22. Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells. PLoS One. 2012; 7(11):e50935. Agra Andrieu N, Motiño O, Mayoral R, Llorente Izquierdo C, Fernández-Alvarez A, Boscá L, Casado M, Martín-Sanz P. PMID: 23226427; PMCID: PMC3511388.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    23. Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma. Oncogenesis. 2012 Jul 09; 1:e23. Fernández-Alvarez A, Llorente-Izquierdo C, Mayoral R, Agra N, Boscá L, Casado M, Martín-Sanz P. PMID: 23552739; PMCID: PMC3412654.
      View in: PubMed   Mentions: 12  
    24. Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis. Am J Pathol. 2011 Mar; 178(3):1361-73. Llorente Izquierdo C, Mayoral R, Flores JM, García-Palencia P, Cucarella C, Boscá L, Casado M, Martín-Sanz P. PMID: 21356386; PMCID: PMC3069875.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    25. Impairment of transforming growth factor beta signaling in caveolin-1-deficient hepatocytes: role in liver regeneration. J Biol Chem. 2010 Feb 05; 285(6):3633-3642. Mayoral R, Valverde ÁM, Llorente Izquierdo C, González-Rodríguez Á, Boscá L, Martín-Sanz P. PMID: 19966340; PMCID: PMC2823504.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    Ana's Networks
    Concepts (156)
    Derived automatically from this person's publications.
    Co-Authors (21)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department